Overcoming matrix interference: ADA immunoassays using an automated nanoliter platform
In this webinar, we present strategies for choosing the right bioanalytical platform to optimize clinical ADA assay method development.
Matrix interference in anti-drug antibody (ADA) assays can present challenges in assay development and data analysis, particularly in clinical study samples. One strategy for reducing matrix interference is the utilization of a nanoliter-scale, flow-through microfluidic immunoassay platform. This webinar will present a case study highlighting the advantages of using the Gyrolab® platform in clinical ADA method development to minimize matrix interference. The case study will also compare this platform to other assay formats and platforms that are commonly used in clinical ADA method development.
What will you learn?
- Understand the flow-through microfluidic assay platform
- Discover the key considerations of clinical ADA assay development strategies and troubleshooting
- Consider the different ADA assay formats and platforms
- Learn the differences and advantages of the Gyrolab® platform compared to standard ELISA for reducing matrix interference, manual labor, reagent consumption and assay incubation time
Who may this interest?
- Bioanalytical Scientists developing biopharmaceuticals (both Biotech/Pharma and CROs)
- Group leaders at Biotech/Pharma
- Directors of Bioanalysis at Biotech, Pharma and CRO companies
- R&D Managers at Biotech and Pharma companies
- Outsourcing Managers at Biotech/Pharma
Speakers
Ellen Lee
Field Applications Scientist
Gyros Protein Technologies (NJ, USA)
Ellen Lee, PhD, joined Gyros Protein Technologies in 2020 and has been focused on helping scientists solve technical problems since graduating from the University of Texas Southwestern Medical Center (TX, USA) in 2015. Ellen previously spent several years supporting biophysical assays and now works with the rest of the Northeast team to ensure that scientists using the Gyrolab platform are supported in their work.
Sally Ye
Senior Scientist, DMPK
Boehringer Ingelheim Pharmaceuticals, Inc. (BI; Ingelheim, Germany)
Ms. Ye received her Bachelor of Science degree in both Chemistry and Life Sciences from the University of British Columbia in Vancouver, Canada. She joined BI in 2016 as an Immunoassay Scientist in the DMPK Bioanalytical Sciences group. She is responsible for developing clinical and non-clinical PK and ADA immunoassay methods as well as monitoring outsourced CRO work. Prior to BI, Ms. Ye worked at CROs where she gained her method development experience in both large and small molecules.
In association with
This webinar was recorded on the 1st February 2024